Merit Medical Lowers 2026 Capital Spending Plan To $60 Million To $70 Million After Solo Pace Deal

The device maker trimmed its spending range from $80 million to $100 million as inventory ate into operating cash flow.

Share
Merit Medical Lowers 2026 Capital Spending Plan To $60 Million To $70 Million After Solo Pace Deal

Merit Medical Systems now expects to spend $60 million to $70 million on property and equipment in 2026, down from the $80 million to $100 million it projected a quarter earlier, according to its 10-Q filed Thursday. The medical device maker also closed its purchase of pacing-device company Solo Pace on October 13.

Both ends of the range come down

The prior quarter's filing guided to about $80 million to $100 million, so the low and the high end were both cut. Merit had spent $45.7 million on property and equipment through nine months, against $57.3 million in the same period a year earlier.

Much of that spending has gone to a new distribution facility in South Jordan, Utah. Construction-in-progress fell by about half, to $40.7 million at September 30 from $82.9 million at December 31, as finished buildings were reclassified.

Merit, which makes catheters, guide wires, stents and other devices for cardiology, radiology, oncology and endoscopy, reported sales of $416.2 million for the third quarter, up 8.4%. Net income was $42.3 million, or $0.70 per share, versus $27.8 million, or $0.46, a year earlier.

Inventory eats into cash flow

Operating cash flow for the first nine months was $175.2 million, down from $198.9 million a year earlier. Cash used to build inventories rose to $59.9 million from $15.1 million.

The company said it is stocking up to keep customer service high, stocking newly acquired products and adding safety stock because of vendor supply delays. Inventories reached $391.0 million at September 30, from $333.7 million at the end of 2025.

Nine-month net income also carried a one-time $5.1 million charge for extra interest on its convertible notes, owed because Merit did not remove restrictive legends on time.

A $45 million cash deal for Solo Pace

On October 13, Merit bought the remaining equity of Solo Pace for $45.0 million in cash, subject to adjustments, plus the settlement of $2.5 million in principal and interest on loans it had made to the company. Solo Pace is now a wholly owned subsidiary.

Merit already held about 18% of Solo Pace, carried at $4.2 million at September 30. Any gain or loss from revaluing that holding at the deal's fair value will hit other income in the fourth quarter.

The deal follows the April purchase of View Point, whose products contributed just $0.1 million of sales in the quarter. The company held $505.8 million of cash and $697 million of available borrowing capacity at September 30.

The fourth-quarter report will show the gain or loss on the old Solo Pace stake, along with where capital spending lands against the new range.

Sources

More on Merit Medical Systems

All Merit Medical Systems (MMSI) coverage →